Core Viewpoint - Invesco Bio-B (09606) saw its stock price rise over 10%, reaching a new high of 480 HKD, following the announcement of its inclusion in the Hang Seng Composite Index and the Stock Connect program, which is expected to enhance its investor base and trading volume [1] Group 1: Stock Performance - Invesco Bio-B's stock increased by 10.85%, trading at 480 HKD with a transaction volume of 579 million HKD [1] - The stock reached a new high, indicating strong market interest and confidence in the company's future prospects [1] Group 2: Company Announcements - The company announced that starting September 8, 2025, its shares will be included in the Hang Seng Composite Index and the Stock Connect program, allowing mainland Chinese investors to directly invest in its shares listed on the Hong Kong Stock Exchange [1] - This inclusion is seen as a recognition of the company's performance and value in the capital market [1] Group 3: Financial Performance - According to Haitong International, Invesco Bio-B reported a revenue of 1.23 billion HKD, primarily due to the recognition of upfront payments from licensing agreements, including 50 million USD from Avenzo and 20 million USD from 3SBio [1] - The company experienced a significant increase in losses, attributed to fair value changes in financial liabilities measured at fair value through profit or loss [1] - The company holds 3.75 billion HKD in cash, which is expected to support clinical and early-stage R&D investments for the next 3 to 5 years [1] Group 4: Collaborations and Future Prospects - The collaboration pipeline with BioNTech is progressing steadily, with early-stage molecules expected to show potential [1]
港股异动 | 映恩生物-B(09606)涨超10%再破顶 进入港股通有望获内资追捧 现金储备充足可支持未来数年研发